Recent Updates
Recently added Catalysts
ALKS Positive Sentiment

Alkermes to Report Second Quarter Financial Results on July 29, 2025 Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 29, 2025 to discuss ...

Key Takeaway: Alkermes plc will host a conference call on July 29, 2025, to discuss its second quarter financial results. The event will be accessible via a webcast and a dedicated phone line for participants. The company is recognized for its innovative medicines in neuroscience and has a strong pipeline for neurological disorders.
Price reaction · baseline $29.69 (2025-07-14 close) · hit after-hours · clean, no other ALKS news in the window
day 0 close · peak
-2.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Alkermes is set to report its second quarter financial results.
  • The company continues to develop innovative medicines in neuroscience.
  • Alkermes has a diverse portfolio addressing significant health issues.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
3.3%
average across 7 past catalysts
Lead asset
N1539
Phase 2 · Hysterectomy

Full Press Release Details

DUBLIN , July 15, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS ) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Tuesday, July 29, 2025 to discuss the company's second quarter financial results.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com . The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.
About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland , Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio . For more information, please visit Alkermes' website at www.alkermes.com .

Frequently Asked Questions

When will Alkermes report its Q2 financial results?

Alkermes will report its Q2 financial results on July 29, 2025.

How can I access the Alkermes conference call?

The conference call can be accessed by dialing +1 877 407 2988 for U.S. callers.

Where can I find the webcast for Alkermes' Q2 results?

The webcast will be available on the Investors section of Alkermes' website.

What is Alkermes known for?

Alkermes is known for developing innovative medicines in neuroscience.

Last updated: Jul 15, 2025